TCGA-AN-A0FT-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 7
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.490
- MYOGENESIS+0.340
- COAGULATION+0.330
- MYC_TARGETS_V2+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- APICAL_SURFACE+0.230
- ESTROGEN_RESPONSE_LATE+0.220
- CHOLESTEROL_HOMEOSTASIS+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- OXIDATIVE_PHOSPHORYLATION+0.190
Top 10 suppressed
- MITOTIC_SPINDLE-0.470
- G2M_CHECKPOINT-0.420
- INTERFERON_ALPHA_RESPONSE-0.400
- E2F_TARGETS-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.320
- INTERFERON_GAMMA_RESPONSE-0.280
- UV_RESPONSE_DN-0.210
- PROTEIN_SECRETION-0.190
- SPERMATOGENESIS-0.170
- ANDROGEN_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9SU-01A-31R-A39I-07 | — | — | 0.830 |
| 2 | MNG589 | — | — | 0.796 |
| 3 | TCGA-B6-A0I5-01A-11R-A034-07 | — | B | 0.791 |
| 4 | 773b41d4-8c43-4777-99b8-190c7e7793e0 | — | — | 0.790 |
| 5 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.784 |
| 6 | MBCProject_0988_T1_RNA | — | B | 0.766 |
| 7 | MNG756 | — | — | 0.745 |
| 8 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.744 |
| 9 | 09f758e5-6be1-4f29-ac92-869d92f8fbcf | — | — | 0.741 |
| 10 | TCGA-E2-A1IF-01A-11R-A144-07 | — | A | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |